Kim Fabiano Marquart — Co-founder, Nerai Bioscience

Kim Fabiano Marquart

Co-founder @Nerai Bioscience

Zurich, Switzerland

I’m a scientist with more than 13 years of training. I am co-founder of Nerai Bioscience, a Zurich (Switzerland) based techbio company developing cures for genetic diseases with CRISPR.

Before that, I studied in Ulm (Germany), Copenhagen (Denmark) and (Switzerland), and sidequested in biopharma (Boehringer Ingelheim, Novartis). I’m extremely curious about biology, biotechnology, consciousness and artificial intelligence.

Now

My role at Nerai is to make sure the gene editing proteins that are engineered in-house are well suited for use in human cells and disease models to progress towards therapy.

Alongside, I read and write a lot.

Publications

Nature Methods2024

Effective genome editing with an enhanced ISDra2 TnpB system and deep learning-predicted ωRNAs

01 / 17

17 papers · 884 citations · h-index 15

h-index by year, citations by month

050 citations a month

Full list on Google Scholar

Assays

.assays-folder{opacity:1!important} .assays-desk{height:auto;padding:0} .assays-folder .folder-root{visibility:visible!important;display:block;width:auto;height:auto} .assays-folder .folder-stage{position:static;cursor:auto} .assays-folder .folder-layer:not(.folder-item),.assays-probe{display:none} .assays-folder .folder-item{position:static;width:min(300px,100%);height:auto;margin-bottom:14px;border-radius:6px;box-shadow:0 0 0 1px rgb(0 0 0/.06),0 2px 6px rgb(0 0 0/.08);cursor:auto} .assays-folder .assay-page{padding-bottom:18px} .assays-folder mark{background-size:100% 100%}

02/2026

Assay title one

The opening paragraph of a short essay goes here. A few sentences that set up the idea and pull the reader into the argument before the text fades out.

A second paragraph continues the thought. It only shows partly, so the card works as a teaser that opens the full piece.

12/2025

Assay title two

Another opening paragraph. The page lies next to the folder with the others, and comes up close when clicked.

More placeholder text to fill the page so the fade at the bottom has something to fade.

09/2025

Assay title three

A third placeholder page. It is the oldest of the three, so it lands furthest from the folder.

More placeholder text to fill the page so the fade at the bottom has something to fade.

Podcast

CRISPRli

My podcast on genome editing, recorded in Zurich: conversations with the researchers behind recent CRISPR work.

All episodes on Spotify

Now

Publications

Effective genome editing with an enhanced ISDra2 TnpB system and deep learning-predicted ωRNAs

Predicting base editing outcomes with an attention-based deep learning algorithm trained on high-throughput target library screens

Programmable genome editing in human cells using RNA-guided bridge recombinases

Predicting prime editing efficiency and product purity by deep learning

Systematic pegRNA design with PRIDICT2.0 and ePRIDICT for efficient prime editing

Continuous directed evolution of a compact CjCas9 variant with broad PAM compatibility

Treatment of a metabolic liver disease in mice with a transient prime editing approach

Spatial profiling of gene editing by in situ sequencing in mice and macaques

Enhancing prime editor activity by directed protein evolution in yeast

Loss of Rnf31 and Vps4b sensitizes pancreatic cancer to T cell-mediated killing

Reduced apoptosis in Chinese hamster ovary cells via optimized CRISPR interference

miRNA engineering of CHO cells facilitates production of difficult-to-express proteins and increases success in cell line development

Predicting adenine base editing efficiencies in different cellular contexts by deep learning

SF3B1 facilitates HIF1-signaling and promotes malignancy in pancreatic cancer

Replacing the SpCas9 HNH domain by deaminases generates compact base editors with an alternative targeting scope

Mutant SF3B1 promotes malignancy in PDAC

Investigation on tissue specific effects of pro-apoptotic micro RNAs revealed miR-147b as a potential biomarker in ovarian cancer prognosis

Assays

Assay title one

Assay title two

Assay title three

Podcast